Idiopathic Pulmonary Fibrosis Prospective Outcomes (IPF-PRO) Registry
Idiopathic Pulmonary Fibrosis prospective outcomes
Sponsor: Boehringer Ingelheim
Enrolling: Male and Female Patients
IRB Number: AAAO3508
U.S. Govt. ID: NCT01915511
Contact: Grace Gallagher: 212-342-1518 /
Additional Study Information: This study is for patients who have been diagnosed Idiopathic Pulmonary Fibrosis (IPF). The purpose of the IPF-PRO registry is to collect data and biological samples that will support future research studies. The IPF-PRO Registry is actively enrolling patients to collect information regarding the natural history of IPF and healthcare interactions. The registry also aims to describe quality of life of IPF participants with patient reported questionnaires and assess the methods of treatment of participants. This registry will collect blood specimens for future research projects. This is an observational registry which means patients will not receive any investigational treatments or investigational drugs, and only minimally invasive procedures will be performed (blood draws via venipuncture). Disease management and treatment decisions will be determined by the patient and their health care professional.
This study is closed
David Lederer, MD
Do You Qualify?
Have you been recently been diagnosed with Idiopathic Pulmonary Fibrosis (IPF)? Yes No
You may be eligible for this study

Place Holder

For more information, please contact:
Grace Gallagher